Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
–
PHILADELPHIA, May 03, 2021 (GLOBE NEWSWIRE) Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced acute safety data from the first dose cohort of the ongoing DesCAARTes™ Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal-dominant pemphigus vulgaris (mPV). We are encouraged by the acute safety profile of DSG3-CAART in this initial low dose cohort. In the first cohort of three patients dosed with DSG3-CAART, there were no clinically relevant adverse events, including cytokine release syndrome or neurotoxicity, during the 8-day acute safety window, which we expect is the period with highest probability of observing treatment-related toxicities. In addition, no dose-limiting toxicities or clinically relevant adverse events were observed in the two patients who have completed more than t
Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m
Share this article
Share this article
BOSTON, April 27, 2021 /PRNewswire/ binx health today announced that the Company s at-home sample collection kits for sexually transmitted infections (STIs) are now available through Walgreens Find Care®, a digital health platform found on the Walgreens app and at Walgreens.com. These collection kits include tests for chlamydia, gonorrhea, syphilis, HIV, HPV as well as other common STIs. We believe that near-consumer healthcare lies at the nexus of testing convenience, rigorous science, and consumer relationships with a rapidly expanding retail health landscape. Partners like Walgreens are vitally important to advancing public health and align with binx s mission of accessible, clinically appropriate testing for all, said binx health CEO Jeffrey Luber. A trusted global brand with millions of loyal customers, Walgreens and the Walgreens Find Care® platform allow more people to quickly and easily get the answers they need. Due to the con
Share this article
Share this article
BEVERLY HILLS, Calif., April 26, 2021 /PRNewswire/ GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company s proprietary natural killer (NK) cell engager, TriKE™ protein biologic technology platform, today announced the appointment of Gregory Berk, M.D., to the position of Chief Medical Officer. Dr. Berk has served as a Director on GT Biopharma s Board since November 2020, and resigns that post in conjunction with his appointment.
The Company is also pleased to announce that Jeffrey S. Miller, M.D., who has supported GT Biopharma as the Company s Consulting Chief Medical Officer since August 2019, will become the Company s Consulting Chief Scientific Officer. Dr. Miller, with his colleagues at the University of Minnesota, is the inventor of the novel TriKE™ technology platform. Dr. Miller will continue his leadership role with respect to the design a